Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

KIN-3248 shows efficacy against tumors with clinically relevant FGFR mutations

Jan. 25, 2022

Qualigen to develop G4-selective transcription inhibitor from UCL for cancer

Jan. 25, 2022

Medshine Discovery synthesizes new ER-alpha degradation inducers

Jan. 25, 2022

Suzhou Vintagence Pharma discloses new GTPase KRAS mutant inhibitors

Jan. 25, 2022

YAP1/TAZ signaling plays a role in colorectal cancer

Jan. 25, 2022

TACH-101 shows activity in gastric and colorectal cancer models

Jan. 24, 2022

IM-1761065, a novel biguanide with promising activity in models of glioblastoma

Jan. 24, 2022

Inventisbio Shanghai discloses GTPase KRAS mutant inhibitors

Jan. 24, 2022

Immunophage Biomedical presents new CCR8 antagonists

Jan. 24, 2022

CDK9 inhibition as promising therapeutic strategy against HCC

Jan. 24, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...